IL-2/IL-15R beta gamma agonist dosing regimens for treating cancer or infectious diseases
AssigneeCytune Pharma
InventorsUlrich Moebius, David Bechard, Irena Adkins, Nada Podzimkova
Life of this patent
Estimating the term…
Abstract
The present invention provides pulsed cyclic administration regimes and pulsed administration regimes for interleukin-2/interleukin-15 receptor βγ (IL-2/IL-15Rβγ) agonists for treating or managing cancer or infectious diseases in human patients. The administration regimes inter alia involve daily administration of IL-2/IL-15Rβγ agonists on 2, 3 or 4 consecutive days followed by days without administration.
Claims18
A method of treating or managing cancer or infectious diseases comprising administering an interleukin-2/interleukin-15 receptor βγ (IL-2/IL-15Rβγ) agonist to a human patient using a cyclical administration regimen, wherein the cyclical administration regimen comprises:
- (a) a first period of x days during which the IL-2/IL-15Rβγ agonist is administered at a daily dose on y consecutive days at the beginning of the first period followed by x-y days without administration of the IL-2/IL-15Rβγ agonist, wherein x is 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or 21 days, and y is 2, 3 or 4 days;
- (b) repeating the first period at least once;
- and
- (c) a second period of z days without administration of the IL-2/IL-15Rβγ agonist, wherein z is 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 28, 35, 42, 49, 56, 63 or 70 days;
- wherein the IL-2/IL-15Rβγ agonist is an interleukin 15 (IL-15)/interleukin-15 receptor alpha (IL-15Rα) complex.
Dependencies are inferred from the claim text.